Denmark: Intellectual Property

Subscribe
Intellectual property law and copyright law thought leadership, articles, podcasts, videos and webinars from expert sources across the legal world. Explore insights covering topics such as licensing and syndication, patent law, trade secrets and trademark law.
Article
AI And Copyright: What Are The Implications Of The Getty And Gema Cases For The Danish Corporate Sector?
Two recent European court cases—Getty Images vs Stability AI and Gema vs OpenAI—have delivered contrasting rulings on generative AI and copyright infringement, with significant implications for how businesses assess legal risks when using AI models. While one court found no infringement in AI training processes, the other ruled that memorized copyrighted content in model outputs constitutes unlawful reproduction, highlighting the urgent need for Danish companies to clarify their AI roles and imp
Denmark IP
B
Bech-Bruun
See more
Article
AI And Copyright: What Are The Implications Of The Getty And Gema Cases For The Danish Corporate Sector?
Two recent European court cases—Getty Images vs Stability AI and Gema vs OpenAI—have delivered contrasting rulings on generative AI and copyright infringement, with significant implications for how businesses assess legal risks when using AI models. While one court found no infringement in AI training processes, the other ruled that memorized copyrighted content in model outputs constitutes unlawful reproduction, highlighting the urgent need for Danish companies to clarify their AI roles and imp
Denmark IP
B
Bech-Bruun
See more
Article
Playing Loose – CJEU Asked To Decide On Combination SPCs
The EU Court of Justice faces a pivotal decision on whether medicines approved as monotherapy but labeled for use in combination with other drugs qualify for Supplementary Protection Certificate (SPC) protection as combinations of active ingredients. This referral, stemming from Genmab's attempts to secure SPC protection for loose combinations including daratumumab, could resolve over a decade of legal uncertainty and fundamentally reshape how pharmaceutical companies approach regulatory strategy for combin
Denmark IP
HL
HGF Ltd
See more
See more